Eplerenone (Inspra) is a selective aldosterone antagonist widely used in the treatment of heart failure after myocardial infarction and the control of hypertension in adults. As a prescription drug, its circulation and use are subject to strict supervision.

What Are the Purchase Channels for Eplerenone (Inspra)?

Overseas Purchase

(1) Patients can choose to consult and purchase from hospital pharmacies or licensed pharmacies in countries or regions where eplerenone has been marketed.

(2) Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budget and planning before purchasing.

Purchase through Medical Service Institutions

(1) Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

(2) These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing and Using Eplerenone (Inspra)

Absolute Contraindicated Populations

(1) Patients with an initial serum potassium level >5.5 mEq/L.

(2) Patients with renal insufficiency whose creatinine clearance rate ≤30 mL/min.

(3) Patients concurrently using strong CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, etc.).

Additional Contraindications for Hypertensive Patients

(1) Patients with type 2 diabetes mellitus accompanied by microalbuminuria.

(2) Male patients with serum creatinine >2.0 mg/dL or female patients with serum creatinine >1.8 mg/dL.

(3) Creatinine clearance rate <50 mL/min.

(4) Patients concurrently using potassium supplements or potassium-sparing diuretics.

Mandatory Tests Before Medication

(1) Determination of serum potassium level.

(2) Renal function assessment (calculation of creatinine clearance rate).

(3) Routine urine test.

Serum Potassium Monitoring

(1) Must be tested before starting treatment.

(2) Re-examined within the first week of treatment.

(3) Tested again one month after starting treatment or adjusting the dosage.

(4) Regular and continuous monitoring in subsequent periods.

Identification of Authentic Eplerenone (Inspra)

Standard Features of Packaging and Labeling

(1) 25mg tablets: Yellow diamond-shaped biconvex film-coated tablets, engraved with "VLE" on one side and "NSR" and "25" on the other side.

(2) 50mg tablets: Yellow diamond-shaped biconvex film-coated tablets, engraved with "VLE" on one side and "NSR" and "50" on the other side.

Standard Drug Properties

(1) The drug substance should be a white to off-white crystalline powder.

(2) The color of the tablets is consistent with that specified in the package insert.

(3) No abnormal odor.